ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented